That was our that was kind of the design we had in mind. We found that the way we give testastron with the ijectable, we don't always get that o high and low. Sometimes the min testostron can stay up quite high. But our idea was the cancer reacts to the environment. So at the beginning, when you first give the shot a, the receptor level an the cancer are quite high. So you're sort of overdosing the cell. The cells want to adapt, and they want to drop their receptor back low again in response to high test astrom. And we thought when they did that, they'd be susceptible to low test astrom again. So we would sort of get em get those cells catout both ways. If they tried to adapt and not be sensitive, they would make themselves sensitive when we dropped the testostrom back. That's what became of the word by pole. We. Soe have these. Ye, i like it. I actually stole it, so i have to credit you with this. So a, i was talking to a a scientist from israel that is using contrasting oxygen to a cure. Longhall cove it, and he kept calling it some some really clumsy name. And so i said, oh, you mean by polar oxygen theropy? He's like, i like that. We're going to use that. So i have to credit you with my brilliant i do get a lot of evecracions ot a set to attend psychiatricl owell, i bet, i bet that's fin. So am testastroincipiete has a pomico cinetic profile that a lot of physicians don't know.